Form 8-K - Current report:
SEC Accession No. 0001193125-25-129524
Filing Date
2025-05-28
Accepted
2025-05-28 16:38:43
Documents
12
Period of Report
2025-05-28
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d40487d8k.htm   iXBRL 8-K 26473
  Complete submission text file 0001193125-25-129524.txt   140424

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ntla-20250528.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20250528_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20250528_pre.xml EX-101.PRE 11260
14 EXTRACTED XBRL INSTANCE DOCUMENT d40487d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 25995956
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)